All In Biotech

Drug Trial Radar · NCT04262856

Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer

A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: Jun 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 151 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

151

Actual

Start

May 28, 2020

Primary completion

Jul 9, 2025

Study completion Jul 9, 2025

Sponsor

Lead sponsor
Arcus Biosciences, Inc.Industry
Sponsor type
Industry
Collaborators
Gilead Sciences
First posted
Feb 10, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This randomized phase 2 open-label study will evaluate the safety and efficacy of zimberelimab (AB122) monotherapy, domvanalimab (AB154) in combination with zimberelimab, and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer.

Conditions

  • Non Small Cell Lung Cancer
  • Nonsquamous Non Small Cell Lung Cancer
  • Squamous Non Small Cell Lung Cancer
  • Lung Cancer

Interventions

  • DomvanalimabDrug

    Domvanalimab is a humanized monoclonal antibody targeting human TIGIT

  • EtrumadenantDrug

    Etrumadenant is an A2aR and A2bR antagonist

  • ZimberelimabDrug

    Zimberelimab is a fully human anti-PD-1 monoclonal antibody

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
  2. Progression-free survival (PFS)Time frame: From randomization until the first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)

Locations

44 sites in 7 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Innovative Clinical Research Institute (ICRI)

    Whittier, California

  • Florida Cancer Specialists

    Englewood, Florida

  • Florida Cancer Specialists

    Gainesville, Florida

  • Florida Cancer Specialists - Panhandle

    Tallahassee, Florida

  • Florida Cancer Specialists - East

    West Palm Beach, Florida

  • Baptist Health Lexington

    Lexington, Kentucky

  • Norton Cancer Institute

    Louisville, Kentucky

  • Ochsner Clinic Foundation

    New Orleans, Louisiana

  • The Valley Hospital - Valley Health System - The Robert and Audrey Luckow Pavilion

    Ridgewood, New Jersey

  • Clinical Research Alliance

    Lake Success, New York

  • Northwell Health Cancer Institute

    Lake Success, New York

  • Wake Forest Baptist Health

    Winston-Salem, North Carolina

  • Allegheny General Hospital (AGH)-Alleghney Singer Research Institute

    Pittsburgh, Pennsylvania

  • Sarah Cannon Research Institute

    Nashville, Tennessee

  • The Center For Cancer And Blood Disorders (Texas Cancer Care)

    Fort Worth, Texas

  • Millennium Oncology

    Houston, Texas

  • Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care

    Blacksburg, Virginia

  • Virginia Cancer Specialists

    Fairfax, Virginia

  • Border Medical Oncology

    Albury, Australia

  • Coffs Harbour Health Campus

    Coffs Harbour, Australia

  • Adelaide Cancer Centre

    Elizabeth Vale, Australia

  • Shoalhaven Cancer Care Centre

    Nowra, Australia

  • McGill University Health Centre (MUHC) - The Montreal Children's Hospital (MCH)

    Montreal, Canada

  • Hong Kong United Oncology Centre

    Hong Kong, Hong Kong

  • Queen Elizabeth Hospital (Hong Kong)

    Hong Kong, Hong Kong

  • Curie Oncology

    Singapore, Singapore

  • Kosin University Gospel Hospital

    Busan, South Korea

  • Chungbuk National University Hospital (CBNUH)

    Cheongju-si, South Korea

  • Chonnam University Hospital

    Hwasun, South Korea

  • Gachon University Gil Medical Center

    Incheon, South Korea

  • Chonbuk National University Hospital

    Jeonju, South Korea

  • Seoul National University Bundang Hospital

    Seongnam-si, South Korea

  • Asan Medical Center

    Seoul, South Korea

  • Kangbuk Samsung Hospital

    Seoul, South Korea

  • Korea University Anam Hospital

    Seoul, South Korea

  • St Vincent Hospital of the Catholic University of Korea

    Suwon, South Korea

  • Catholic University of Korea, Uijeongbu St. Mary's Hospital

    Uijeongbu-si, South Korea

  • Taipei Medical University - Shuang Ho Hospital

    New Taipei City, Taiwan

  • Chi Mei Hospital

    Tainan, Taiwan

Showing 40 of 44 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.